13F Filings History of Caligan Partners LP
- Latest 13F filing
- Q1 2026 - 15 May 2026
- Latest reported 13F value
- $1,413,845,692
- Largest 13F holdings
-
LQDA ABVX RVMD PCVX XENE MLYS EXEL TNGX TYRA SYRE ADMA LBRX
+8 more
VOR SABS IRD IVA MBX AVTX ANIK MAZE - Form 13F summary
-
- Caligan Partners LP Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Caligan Partners LP reported 24 equity holdings with a total reported market value of $1,413,845,692 for Q1 2026. Top reported holdings included LQDA, ABVX, RVMD, PCVX, and XENE.
- Manager signature
- Tiffany Crowley - Chief Financial Officer/Chief Compliance Officer
- Manager location
- New York, NY
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Caligan Partners LP with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q1 2026
Latest value
$1,413,845,692
Quarter delta
+$321,399,212
Accepted
15 May 2026, 09:14
Rows shown
1-14 of 14
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 24 | $1,413,845,692 | +$351,562,925 | -$77,651,314 | +$273,911,611 | LQDA, ABVX, RVMD, PCVX, XENE | 13F-HR | 15 May 2026, 09:14 |
| Q4 2025 | 20 | $1,092,446,480 | +$222,753,336 | -$92,649,833 | +$130,103,503 | LQDA, ABVX, RVMD, MLYS, PCVX | 13F-HR | 17 Feb 2026, 16:58 |
| Q3 2025 | 16 | $720,669,772 | +$142,197,155 | -$224,287,652 | -$82,090,497 | LQDA, ABVX, MLYS, EXEL, RVMD | 13F-HR | 14 Nov 2025, 17:02 |
| Q2 2025 | 16 | $515,131,469 | +$51,300,066 | -$48,177,999 | +$3,122,067 | VRNA, LQDA, EXEL, AGIO, MRUS | 13F-HR | 14 Aug 2025, 17:01 |
| Q1 2025 | 16 | $479,228,892 | +$50,267,019 | -$1,062,750 | +$49,204,269 | LQDA, VRNA, EXEL, MLYS, EOLS | 13F-HR | 15 May 2025, 16:25 |
| Q4 2024 | 14 | $394,876,202 | +$52,997,208 | -$6,832,378 | +$46,164,830 | LQDA, VRNA, EXEL, EOLS, ANIK | 13F-HR | 14 Feb 2025, 17:07 |
| Q3 2024 | 12 | $315,472,882 | +$14,372,861 | -$151,501,202 | -$137,128,341 | LQDA, VRNA, EXEL, EOLS, ANIK | 13F-HR | 14 Nov 2024, 17:15 |
| Q2 2024 | 13 | $427,996,461 | +$61,011,207 | -$62,792 | +$60,948,415 | LQDA, ALIM, ANIK, EXEL, BCRX | 13F-HR | 14 Aug 2024, 15:57 |
| Q1 2024 | 12 | $378,314,062 | +$66,891,066 | -$25,792,633 | +$41,098,433 | LQDA, ALIM, ANIK, EOLS, EXEL | 13F-HR | 13 May 2024, 16:10 |
| Q4 2023 | 11 | $296,522,630 | +$30,164,535 | -$6,707,792 | +$23,456,743 | LQDA, ALIM, ANIK, EXEL, LAB | 13F-HR | 14 Feb 2024, 14:36 |
| Q3 2023 | 12 | $195,507,783 | +$58,856,275 | -$21,050,167 | +$37,806,108 | LQDA, ALIM, LAB, ANIK, EXEL | 13F-HR | 14 Nov 2023, 08:39 |
| Q2 2023 | 12 | $164,541,962 | +$17,331,291 | -$4,305,356 | +$13,025,935 | LQDA, ANIK, EXEL, LAB, ICPT | 13F-HR | 14 Aug 2023, 17:17 |
| Q1 2023 | 11 | $143,374,414 | +$20,048,752 | -$5,977,452 | +$14,071,300 | LQDA, ANIK, LAB, EXEL, EOLS | 13F-HR | 15 May 2023, 08:46 |
| Q4 2022 | 11 | $120,160,498 | $0 | $0 | $0 | LQDA, ANIK, EOLS, ADMA, LAB | Restatement | 15 May 2023, 09:34 |